Navigation Links
Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
Date:11/16/2010

>CAMBIA is not indicated for prophylactic therapy or for cluster headache.

Important Safety Information (United States)

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS NSAIDs, including CAMBIA, may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use or in patients with CV disease or risk factors for CV disease. CAMBIA is contraindicated for peri-operative pain in coronary artery bypass graft surgery. NSAIDs increase the risk of gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk.

Use the lowest effective dose for the shortest possible duration. Long-term administration of NSAIDs can result in serious and potentially fatal events, including CV thrombotic events or GI reactions.

CAMBIA is contraindicated in patients with hypersensitivity to diclofenac or other NSAIDs, and in patients with preexisting asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic-like reactions have been reported in such patients. Anaphylactic reactions may also occur in patients with the aspirin triad or in patients without prior exposure to CAMBIA. CAMBIA is contraindicated in patients with the aspirin triad. Discontinue immediately if an anaphylactic reaction occurs.

Renal papillary necrosis and other renal injury may occur with long-term use of NSAIDs. Use CAMBIA with caution in patients at risk, including the elderly, those taking diuretics or ACE inhibitors, those with renal impairment, heart failure, or liver impairment. CAMBIA is not recommended in patients with advanced renal disease.

Use caution when prescribing CAMBIA with drugs known to be
'/>"/>

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
2. US WorldMeds Acquires Solstice Neurosciences
3. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
4. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
5. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
6. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
7. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
8. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... California , September 1, 2015 ... is segmented on the basis of sectors, products ... chronic diseases globally coupled with the increasing demand ... diseases are expected to propel the growth for ... manage biological information efficiently is known as bioinformatics. ...
(Date:9/1/2015)... Aug. 31, 2015 Research and Markets ( ... "Regulatory Affairs for Support Staff (London, UK - September ... This two day course provides an introduction to ... and has been designed specifically for those working in ... gain an overview of EU regulatory procedures required to ...
(Date:9/1/2015)... 2015 - The ... egistry data presented at ESC Congress ... the evolution of manag ing AF in ... -   The first-ever two-year outcomes from the Global Anticoagulant ... expose that all-cause death was the most frequent major event in more than ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
... U.S. Food and Drug Administration today approved Ferriprox (deferiprone) ... transfusions in patients with thalassemia, a genetic blood disorder ... prior chelation therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... iron in the body from the frequent blood transfusions ...
... SAN RAMON, Calif., Oct. 14, 2011 Armanino ... successful company-wide Microsoft Dynamics AX implementation and the ... MES (Manufacturing Engineering System) to streamline the production ... equipment.  Microsoft Dynamics AX is a comprehensive business ...
Cached Medicine Technology:FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 2FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 3Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 2Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... not managed, stress created from everyday life changes can lead to very serious, ... provide support for coping with stress. Herbal supplement manufacturer MediHerb has ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia ... and universities across the country in stemming sexual assaults on their campuses. , ... (ARC3), a consortium of sexual assault researchers and student affairs professionals responding to ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... negative pressure inside a wound to remove exudates, fluid, and infectious materials to ... portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected to expand ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to benefit the patients ... Valley Country Club in Lafayette Hill, PA. Over the past 26 years, the Classic, ... programs and services designed to support patients and their families during their time at ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Royal River ... new study that followed men and women for 19 years and found that, among ... did not take multivitamins. , The report is part of the September 2015 issue ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... awareness of maritime pollution and secure a place in history ... Pacific Ocean from San Francisco on Thursday. ... her lightweight 24-foot (seven meter) silver rowing boat and is ... trek across the vast expanse of the Pacific. ...
... Trump has confirmed that she is set to marry her ... ,However, the confirmation will come as a surprise to her ... ,The ex-wife of Donald Trump revealed her plans to become ... she writes a weekly advice column. ,The 58-year-old ...
... she often surfs porn websites, for she believes that it ... ,The estranged wife of rocker Marilyn Manson feels that ... ,"Amateur pornography is a great thing. You can find ... saying. ,She insists that she is just like ...
... involved in some of the highest-profile health scares involving ... product safety, a top official said Friday. ... fundamental problems behind issues relating to food product safety," ... top product safety agency told a news conference. ...
... 20 million pounds to his estranged wife Heather Mills in ... million pounds, if reports are to be believed. ... in the range of somewhere between 25 to 30 million ... ,However, their stubbornness is now indicating that they ...
... Indian Council of Medical Research Director-General N. K. Ganguly on ... trials conducted in India would be registered. These trials ... ,The national registry will make the trails more transparent. It ... researcher who plans to conduct drug trials on humans is ...
Cached Medicine News:Health News:Briton Set for Pacific Solo Odyssey to Highlight Warming 2Health News:China Vows to Improve Food Safety in Wake of Health Scares 2Health News:Clinical Trials Registry Launched in India 2
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: